These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 12107582

  • 1. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia.
    Chan YL, Pang LM, Chik KW, Cheng JC, Li CK.
    Pediatr Radiol; 2002 Jul; 32(7):492-7. PubMed ID: 12107582
    [Abstract] [Full Text] [Related]

  • 2. Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth.
    Chan YL, Li CK, Pang LM, Chik KW.
    Clin Radiol; 2000 Aug; 55(8):610-4. PubMed ID: 10964732
    [Abstract] [Full Text] [Related]

  • 3. The radiological appearances of thalassaemia.
    Tyler PA, Madani G, Chaudhuri R, Wilson LF, Dick EA.
    Clin Radiol; 2006 Jan; 61(1):40-52. PubMed ID: 16356815
    [Abstract] [Full Text] [Related]

  • 4. [The evolutionary effects of therapy on the skeletal lesions in beta-thalassemia].
    Orzincolo C, Castaldi G, Bariani L, Scutellari PN.
    Radiol Med; 1994 Apr; 87(4):381-8. PubMed ID: 8190918
    [Abstract] [Full Text] [Related]

  • 5. Deferoxamine-induced bone dysplasia in patients with thalassemia major.
    Brill PW, Winchester P, Giardina PJ, Cunningham-Rundles S.
    AJR Am J Roentgenol; 1991 Mar; 156(3):561-5. PubMed ID: 1899759
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine.
    De Sanctis V, Stea S, Savarino L, Scialpi V, Traina GC, Chiarelli GM, Sprocati M, Govoni R, Pezzoli D, Gamberini R, Rigolin F.
    J Pediatr Endocrinol Metab; 1998 Mar; 11 Suppl 3():827-33. PubMed ID: 10091153
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up of skeletal dysplasia in thalassaemia major.
    Naselli A, Vignolo M, Di Battista E, Garzia P, Forni GL, Traverso T, Aicardi G.
    J Pediatr Endocrinol Metab; 1998 Mar; 11 Suppl 3():817-25. PubMed ID: 10091152
    [Abstract] [Full Text] [Related]

  • 8. Deferoxamine-induced bone dysplasia in the distal femur and patella of pediatric patients and young adults: MR imaging appearance.
    Chan Y, Li C, Chu WC, Pang L, Cheng JC, Chik KW.
    AJR Am J Roentgenol; 2000 Dec; 175(6):1561-6. PubMed ID: 11090375
    [Abstract] [Full Text] [Related]

  • 9. Deferoxamine-induced dysplasia of the knee: sonographic features and diagnostic performance compared with magnetic resonance imaging.
    Chan YL, Chu CW, Chik KW, Pang LM, Shing MK, Li CK.
    J Ultrasound Med; 2001 Jul; 20(7):723-8. PubMed ID: 11444730
    [Abstract] [Full Text] [Related]

  • 10. Deferoxamine-induced dysplasia-like skeletal abnormalities at radiography and MRI.
    Seif El Dien HM, Esmail RI, Magdy RE, Lotfy HM.
    Pediatr Radiol; 2013 Sep; 43(9):1159-65. PubMed ID: 23563594
    [Abstract] [Full Text] [Related]

  • 11. MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.
    Miller TT, Caldwell G, Kaye JJ, Arkin S, Burke S, Brill PW.
    Pediatr Radiol; 1993 Sep; 23(7):523-4. PubMed ID: 8309753
    [Abstract] [Full Text] [Related]

  • 12. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine.
    De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, Vullo C.
    Eur J Pediatr; 1996 May; 155(5):368-72. PubMed ID: 8741032
    [Abstract] [Full Text] [Related]

  • 13. [Anomalies of the masticatory apparatus in beta-thalassemia. The present status after transfusion and iron-chelating therapy].
    Scutellari PN, Orzincolo C, Andraghetti D, Gamberini MR.
    Radiol Med; 1994 Apr; 87(4):389-96. PubMed ID: 8190919
    [Abstract] [Full Text] [Related]

  • 14. Case report 744. Deferoxamine-induced skeletal dysplasia.
    Borenstein ZC, Hyman CB, Rimoin DL, Chapman CL, Lachman R.
    Skeletal Radiol; 1992 Apr; 21(8):534-7. PubMed ID: 1465648
    [No Abstract] [Full Text] [Related]

  • 15. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C, La Nasa G, Contu L, Galimberti M, Polchi P, Angelucci E, Baronciani D, Barbanti I, Muretto P, Lucarelli G.
    Bone Marrow Transplant; 1993 Apr; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract] [Full Text] [Related]

  • 16. Cardiac disease in beta-thalassaemia major: Is it reversible?
    Atiq M, Bana M, Ahmed US, Bano S, Yousuf M, Fadoo Z, Khurshid M.
    Singapore Med J; 2006 Aug; 47(8):693-6. PubMed ID: 16865210
    [Abstract] [Full Text] [Related]

  • 17. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM, Cheuk DK, Ha SY, Chiang AK, Chan GC.
    Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
    [No Abstract] [Full Text] [Related]

  • 18. Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients.
    Levin TL, Sheth S, Berdon WE, Ruzal-Shapiro C, Piomelli S.
    Pediatr Radiol; 1995 Nov; 25 Suppl 1():S122-4. PubMed ID: 8577502
    [Abstract] [Full Text] [Related]

  • 19. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA, Mohamed NA, El-Metwally TH, Kamal MM.
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [Abstract] [Full Text] [Related]

  • 20. [Pyle's metaphyseal dysplasia].
    Mabille JP, Benoit JP, Castera D.
    Ann Radiol (Paris); 1973 May; 16(11):723-30. PubMed ID: 4779476
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.